NASDAQ:PRAH

PRA Health Sciences Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$165.21
0.00 (0.00 %)
(As of 07/1/2021)
Add
Compare
Today's Range
$165.21
$165.21
50-Day Range
$165.21
$174.52
52-Week Range
$93.00
$175.95
Volume57 shs
Average Volume837,472 shs
Market Capitalization$10.70 billion
P/E Ratio50.52
Dividend YieldN/A
Beta1.31

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.


PRA Health Sciences logo

About PRA Health Sciences

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.00 out of 5 stars

Medical Sector

558th out of 1,351 stocks

Commercial Physical Research Industry

10th out of 25 stocks

Analyst Opinion: 1.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

Is PRA Health Sciences a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PRA Health Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRAH, but not buy additional shares or sell existing shares.
View analyst ratings for PRA Health Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than PRA Health Sciences?

Wall Street analysts have given PRA Health Sciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PRA Health Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences, Inc. (NASDAQ:PRAH) issued its earnings results on Wednesday, April, 28th. The medical research company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.32 by $0.03. The medical research company earned $933.78 million during the quarter, compared to the consensus estimate of $863.45 million. PRA Health Sciences had a net margin of 6.40% and a trailing twelve-month return on equity of 20.49%. PRA Health Sciences's quarterly revenue was up 19.1% on a year-over-year basis. During the same quarter last year, the company posted $1.05 earnings per share.
View PRA Health Sciences' earnings history
.

What price target have analysts set for PRAH?

6 equities research analysts have issued 12-month target prices for PRA Health Sciences' stock. Their forecasts range from $155.00 to $175.00. On average, they anticipate PRA Health Sciences' stock price to reach $167.80 in the next year. This suggests a possible upside of 1.6% from the stock's current price.
View analysts' price targets for PRA Health Sciences
or view top-rated stocks among Wall Street analysts.

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the following people:
  • Mr. Colin Shannon, Chairman, CEO & Pres (Age 62, Pay $2.03M)
  • Mr. Michael J. Bonello, Exec. VP & CFO (Age 51, Pay $809.42k)
  • Mr. Christopher L. Gaenzle, Exec. VP, Chief Admin. Officer, Gen. Counsel & Corp. Sec. (Age 54, Pay $853.97k)
  • Ms. Margaret Keegan, Exec. VP & COO
  • Mr. Kent Thoelke, Exec. VP & Chief Scientific Officer
  • Mr. Thomas Byrne, VP of Legal Affairs
  • Laurie Hurst, Sr. Director of Communications & PR
  • Ms. Tami Klerr-Naivar, Exec. VP and Chief Sales & Marketing Officer
  • Mr. Patrick R. Spine, VP of HR (Age 50)
  • Dr. Michael Kirchengast, Sr. VP of Scientific Affairs

What is Colin Shannon's approval rating as PRA Health Sciences' CEO?

500 employees have rated PRA Health Sciences CEO Colin Shannon on Glassdoor.com. Colin Shannon has an approval rating of 87% among PRA Health Sciences' employees.

Who are some of PRA Health Sciences' key competitors?

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Applied Materials (AMAT), Abbott Laboratories (ABT), The Walt Disney (DIS), PayPal (PYPL), Veeva Systems (VEEV), Pfizer (PFE) and AbbVie (ABBV).

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.73%), Millennium Management LLC (5.76%), Massachusetts Financial Services Co. MA (5.00%), HBK Investments L P (4.90%), Vanguard Group Inc. (2.74%) and Alpine Associates Management Inc. (2.32%). Company insiders that own PRA Health Sciences stock include Christopher L Gaenzle, Colin Shannon, Michael J Bonello and Nick Rosenberg.
View institutional ownership trends for PRA Health Sciences
.

Which institutional investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Price T Rowe Associates Inc. MD, Massachusetts Financial Services Co. MA, BlackRock Inc., Geode Capital Management LLC, Invesco Ltd., State Street Corp, and FMR LLC. Company insiders that have sold PRA Health Sciences company stock in the last year include Christopher L Gaenzle, Colin Shannon, Michael J Bonello, and Nick Rosenberg.
View insider buying and selling activity for PRA Health Sciences
or view top insider-selling stocks.

Which institutional investors are buying PRA Health Sciences stock?

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, HBK Investments L P, Glazer Capital LLC, Ergoteles LLC, Goldman Sachs Group Inc., Natixis, Virtu Financial LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for PRA Health Sciences
or or view top insider-buying stocks.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $165.21.

How much money does PRA Health Sciences make?

PRA Health Sciences has a market capitalization of $10.70 billion and generates $3.18 billion in revenue each year. The medical research company earns $197.04 million in net income (profit) each year or $3.90 on an earnings per share basis.

How many employees does PRA Health Sciences have?

PRA Health Sciences employs 18,100 workers across the globe.

What is PRA Health Sciences' official website?

The official website for PRA Health Sciences is www.prahs.com.

Where are PRA Health Sciences' headquarters?

PRA Health Sciences is headquartered at 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at (919) 786-8200 or via email at [email protected]


This page was last updated on 9/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.